PharmaCast Production Pilot — Phase 3

project 19014efffc7f9ec2
Normalized: pharmacast production pilot phase 3
moreland_contracts
Entity Properties (gold project table)
project_id
19014efffc7f9ec2
name
PharmaCast Production Pilot — Phase 3
client_id
canonical_metadata
created_at
2026-05-03 02:27:33.687576+00:00
updated_at
2026-05-03 02:27:33.687576+00:00
status
billable
recurring
squad
qa_partner
project_manager
lead_dev
description
state
team_name
closedate
dealstage
deal_amount
contract_type
contract_hourly_rate
contract_estimated_hours
contract_total_fee
22%
Separation Confidence How distinct this entity is from others. Higher means no close matches existed when it was created. Lower means a near-match was rejected just below the 80% threshold — worth reviewing.
Low — a near-match was rejected, review recommended
100%
Avg Match Confidence The average confidence score across all active source mappings. Shows overall quality of linkage between source records and this canonical entity.
Strong source linkage

Source Mappings (3)

Source Source ID Display Name Confidence Method Status Actions
moreland_contracts eaa57f0ee76c3e638a3bc38f2c1cb902 PharmaCast Production Pilot — Phase 3 1.00 fuzzy+embedding Active
Source Record bronze_moreland_contracts_ma_project_contracts
file_hash
eaa57f0ee76c3e638a3bc38f2c1cb902
file_name
Seeber - PharmaCast Phase 3 - Arrangement Letter - 2026-04-30.docx
file_path
https://morelandpartners.sharepoint.com/sites/MorelandConnect-BusinessDevelopment/_layouts/15/Doc.aspx?sourcedoc=%7B81B94F33-82D5-4966-81D8-0179D70C1841%7D&file=Seeber%20-%20PharmaCast%20Phase%203%20-%20Arrangement%20Letter%20-%202026-04-30.docx&action=default&mobileredirect=true
company
Seeber Lifesciences, LLC
project_name
PharmaCast Production Pilot — Phase 3
contact_person
Eric
contract_type
time_and_materials
hourly_rate
250.0
estimated_hours
250.0
total_fee_estimate
62500.0
brief_project_description
Consulting services to assist Seeber with Phase 3 of the PharmaCast Production Pilot, focusing on product improvements and strategic readiness.
start_date
extracted_at
2026-06-15T02:17:55.250150+00:00
raw_text_preview
April 30, 2026 Re: PharmaCast Production Pilot — Phase 3 Dear Eric: MorelandConnect LLC (“Moreland”) is pleased to provide this Arrangement Letter (“Agreement”) confirming our consulting services (the “Services”) to assist Seeber Lifesciences, LLC f/k/a Seeber Farms Management (“Seeber”) with Phase 3 of the PharmaCast Production Pilot (the “Project”). Background Seeber and Moreland have partnered across the PharmaCast Discovery, MVP, and Phase 2 Production Pilot engagements to deliver a professional-grade pharmaceutical forecasting platform incorporating advanced AI research, refined forecasting capabilities, and a production-quality user experience. Phase 2 is nearing completion and is currently in external beta testing with pharmaceutical forecasting subject-matter experts identified by Seeber. Feedback on functionality has been strong, and several enhancement opportunities have been identified that will materially improve the platform’s value, consistency, and presentation quality ahead of Seeber’s planned strategic-partner and go-to-market conversations. This Arrangement Letter scopes “Phase 3.1”—the strategic-readiness set of product improvements to be completed prior to end of June 2026, in support of Seeber’s planned discussions with potential acquirers and strategic partners. Backend, pilot-readiness, and commerce items (e.g., subscription billing, Stripe integration) are explicitly deferred to a subsequent Phase and are not included in this Agreement. Scope of Services Moreland will provide consulting services to assist Seeber with the following: In Scope • Model Template Updates: Incorporate updated forecast model templates provided by Seeber based on beta-tester feedback. Update the platform to accept and reflect revised flows, inputs, and outputs end-to-end, including new assumption rationale and source metadata provided alongside each input. • Model Selection Prompt / Guided Setup: Add a lightweight guided prompt during new-forecast creation that asks
file_created_at
2026-05-01T18:24:36+00:00
file_modified_at
2026-05-01T18:24:35+00:00
created_by
Paul Franke
modified_by
Paul Franke
_dlt_meta
moreland_contracts 5271dc12d3ebc638b027545eb3f893ce PharmaCast Production Pilot — Phase 3 1.00 exact Active
Source Record bronze_moreland_contracts_ma_project_contracts
file_hash
5271dc12d3ebc638b027545eb3f893ce
file_name
Seeber - PharmaCast Phase 3 - Arrangement Letter - 2026-04-30.docx.pdf
file_path
https://morelandpartners.sharepoint.com/sites/MorelandConnect-BusinessDevelopment/Shared%20Documents/Internal%20-%20Business%20Development/Seeber%20Farms/Signed%20Agreements/Seeber%20-%20PharmaCast%20Phase%203%20-%20Arrangement%20Letter%20-%202026-04-30.docx.pdf
company
Seeber Lifesciences, LLC
project_name
PharmaCast Production Pilot — Phase 3
contact_person
Eric
contract_type
time_and_materials
hourly_rate
estimated_hours
0.0
total_fee_estimate
brief_project_description
Consulting services to assist Seeber with Phase 3 of the PharmaCast Production Pilot, focusing on strategic-readiness product improvements.
start_date
2026-04-30
extracted_at
2026-07-01T02:19:24.953479+00:00
raw_text_preview
ARRANGEMENT LETTER Page 1 of 7 April 30, 2026 Re: PharmaCast Production Pilot — Phase 3 Dear Eric: MorelandConnect LLC (“Moreland”) is pleased to provide this Arrangement Letter (“Agreement”) confirming our consulting services (the “Services”) to assist Seeber Lifesciences, LLC f/k/a Seeber Farms Management (“Seeber”) with Phase 3 of the PharmaCast Production Pilot (the “Project”). Background Seeber and Moreland have partnered across the PharmaCast Discovery, MVP, and Phase 2 Production Pilot engagements to deliver a professional -grade pharmaceutical forecasting platform incorporating advanced AI research, refined forecasting capabilities, and a production - quality user experience. Phase 2 is nearing completion and is currently in external beta testing with pharmaceutical forecasting subject -matter experts identified by Seeber. Feedback on functionality has been strong, and several enhancement opportunities have been identified that will materially improve the platform’s value, consistency, and presentation quality ahead of Seeber’s planned strategic - partner and go -to-market conversations. This Arrangement Letter scopes “Phase 3.1” —the strategic -readiness set of product improvements to be completed prior to end of June 2026, in support of Seeber’s planned discussions with potential acquirers and strategic partners. Backend, pilot -readiness, and commerce items (e.g., subscription billing, Stripe integration) are explicitly deferred to a subsequent Phase and are not included in this Agreement. Scope of Services Moreland will provide consulting services to assist Seeber with the following: In Scope • Model Template Updates: Incorporate updated forecast model templates provided by Seeber based on beta -tester feedback. Update the platform to accept and reflect revised flows, inputs, and outputs end -to-end, including new assumption rationale and source metadata provided alongsid e each input. • Model Selection Pro
file_created_at
2026-05-07T12:44:08+00:00
file_modified_at
2026-05-07T12:44:08+00:00
created_by
Sam Wilsey
modified_by
Sam Wilsey
_dlt_meta
moreland_contracts b4f5b2bf1064561f2f4a662ad438c0e0 PharmaCast Production Pilot — Phase 3 1.00 exact Active
Source Record bronze_moreland_contracts_ma_project_contracts
file_hash
b4f5b2bf1064561f2f4a662ad438c0e0
file_name
Seeber - PharmaCast Phase 3 - Arrangement Letter - 2026-05-01.pdf
file_path
https://morelandpartners.sharepoint.com/sites/MorelandConnect-BusinessDevelopment/Shared%20Documents/Internal%20-%20Business%20Development/Seeber%20Farms/Working%20Agreements/Seeber%20-%20PharmaCast%20Phase%203%20-%20Arrangement%20Letter%20-%202026-05-01.pdf
company
Seeber Lifesciences, LLC
project_name
PharmaCast Production Pilot — Phase 3
contact_person
Eric
contract_type
time_and_materials
hourly_rate
estimated_hours
0.0
total_fee_estimate
brief_project_description
Consulting services to assist Seeber with Phase 3 of the PharmaCast Production Pilot, focusing on strategic-readiness product improvements.
start_date
2026-05-01
extracted_at
2026-07-02T02:17:18.378407+00:00
raw_text_preview
ARRANGEMENT LETTER Page 1 of 7 May 1, 2026 Re: PharmaCast Production Pilot — Phase 3 Dear Eric: MorelandConnect LLC (“Moreland”) is pleased to provide this Arrangement Letter (“Agreement”) confirming our consulting services (the “Services”) to assist Seeber Lifesciences, LLC f/k/a Seeber Farms Management (“Seeber”) with Phase 3 of the PharmaCast Prod uction Pilot (the “Project”). Background Seeber and Moreland have partnered across the PharmaCast Discovery, MVP, and Phase 2 Production Pilot engagements to deliver a professional -grade pharmaceutical forecasting platform incorporating advanced AI research, refined forecasting capabilities, and a production - quality user experience. Phase 2 is nearing completion and is currently in external beta testing with pharmaceutical forecasting subject -matter experts identified by Seeber. Feedback on functionality has been strong, and several enhancement opportunities have been identified that will materially improve the platform’s value, consistency, and presentation quality ahead of Seeber’s planned strategic - partner and go -to-market conversations. This Arrangement Letter scopes “Phase 3.1” —the strategic -readiness set of product improvements to be completed prior to end of June 2026, in support of Seeber’s planned discussions with potential acquirers and strategic partners. Backend, pilot -readiness, and commerce items (e.g., subscription billing, Stripe integration) are explicitly deferred to a subsequent Phase and are not included in this Agreement. Scope of Services Moreland will provide consulting services to assist Seeber with the following: In Scope • Model Template Updates: Incorporate updated forecast model templates provided by Seeber based on beta -tester feedback. Update the platform to accept and reflect revised flows, inputs, and outputs end -to-end, including new assumption rationale and source metadata provided alongsid e each input. • Model Selection Pro
file_created_at
2026-05-09T17:16:50+00:00
file_modified_at
2026-05-09T17:16:50+00:00
created_by
Jeff Kavlick
modified_by
Jeff Kavlick
_dlt_meta